Page last updated: 2024-09-05

lapatinib and mrk 003

lapatinib has been researched along with mrk 003 in 1 studies

Compound Research Comparison

Studies (lapatinib)	Trials (lapatinib)	Recent Studies (post-2010) (lapatinib)	Studies (mrk 003)	Trials (mrk 003)	Recent Studies (post-2010) (mrk 003)
1,919	305	1,442	30	0	20

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albain, KS; Clementz, AG; Meeke, K; Miele, L; Osipo, C; Pandya, K; Roberts, J; Rogowski, A	1

Other Studies

1 other study(ies) available for lapatinib and mrk 003

Article	Year
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. British journal of cancer, 2011, Sep-06, Volume: 105, Issue:6 Topics: Amyloid Precursor Protein Secretases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cyclic S-Oxides; Drug Resistance, Neoplasm; Female; Gene Targeting; Genes, erbB; Genes, erbB-2; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Recurrence; Signal Transduction; Thiadiazoles; Trastuzumab	2011

Article

Year

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.

British journal of cancer, 2011, Sep-06, Volume: 105, Issue:6

Topics: Amyloid Precursor Protein Secretases; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cyclic S-Oxides; Drug Resistance, Neoplasm; Female; Gene Targeting; Genes, erbB; Genes, erbB-2; Humans; Lapatinib; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Receptors, Notch; Recurrence; Signal Transduction; Thiadiazoles; Trastuzumab

2011